HAYWARD, Calif.--(BUSINESS WIRE)--Jan. 19, 2006--IMPAX Laboratories, Inc. (OTC:IPXL) today announced that it has reached a settlement with an affiliate of Britain’s Shire Pharmaceuticals Group Plc (“Shire”) covering all patent litigation between the parties related to Adderall XR(R) (mixed amphetamine salts). Under the settlement, IMPAX will be permitted to market generic versions of Adderall XR in the United States no later than January 1, 2010. In certain situations, such as the launch of another generic version of Adderall XR, IMPAX may be permitted to enter the market as Shire’s authorized generic. IMPAX will pay Shire a royalty from its generic sales of Adderall XR.
